These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 31095793)

  • 1. Pyridine derivatives as anticancer lead compounds with Fatty Acid Synthase as the target: An in silico-guided in vitro study.
    Amrutha NA; Archana PR; Mohan SG; Anto RJ; Sadasivan C
    J Cell Biochem; 2019 Oct; 120(10):16643-16657. PubMed ID: 31095793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico screening for identification of fatty acid synthase inhibitors and evaluation of their antiproliferative activity using human cancer cell lines.
    Nisthul A A; Retnakumari AP; A S; Anto RJ; Sadasivan C
    J Recept Signal Transduct Res; 2018 Aug; 38(4):335-341. PubMed ID: 30256698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress in the development of fatty acid synthase inhibitors as anticancer targets.
    Mullen GE; Yet L
    Bioorg Med Chem Lett; 2015 Oct; 25(20):4363-9. PubMed ID: 26364942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of de novo Palmitate Synthesis by Fatty Acid Synthase Induces Apoptosis in Tumor Cells by Remodeling Cell Membranes, Inhibiting Signaling Pathways, and Reprogramming Gene Expression.
    Ventura R; Mordec K; Waszczuk J; Wang Z; Lai J; Fridlib M; Buckley D; Kemble G; Heuer TS
    EBioMedicine; 2015 Aug; 2(8):808-24. PubMed ID: 26425687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The selective target of capsaicin on FASN expression and de novo fatty acid synthesis mediated through ROS generation triggers apoptosis in HepG2 cells.
    Impheng H; Pongcharoen S; Richert L; Pekthong D; Srisawang P
    PLoS One; 2014; 9(9):e107842. PubMed ID: 25255125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and anticancer activity of some novel 1H-benzo[d]imidazole-5-carboxamide derivatives as fatty acid synthase inhibitors.
    Singh S; Paul S; Brás NF; Kundu CN; Karthikeyan C; Moorthy NSHN
    Bioorg Chem; 2023 Sep; 138():106658. PubMed ID: 37331170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and therapeutic relevance of the metabolic oncogene fatty acid synthase in HER2+ breast cancer.
    Corominas-Faja B; Vellon L; Cuyàs E; Buxó M; Martin-Castillo B; Serra D; García J; Lupu R; Menendez JA
    Histol Histopathol; 2017 Jul; 32(7):687-698. PubMed ID: 27714708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proton pump inhibitors suppress DNA damage repair and sensitize treatment resistance in breast cancer by targeting fatty acid synthase.
    Wang CJ; Li D; Danielson JA; Zhang EH; Dong Z; Miller KD; Li L; Zhang JT; Liu JY
    Cancer Lett; 2021 Jul; 509():1-12. PubMed ID: 33813001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Galloyl esters of trans-stilbenes are inhibitors of FASN with anticancer activity on non-small cell lung cancer cells.
    Tan YJ; Ali A; Tee SY; Teo JT; Xi Y; Go ML; Lam Y
    Eur J Med Chem; 2019 Nov; 182():111597. PubMed ID: 31422225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological inhibitors of Fatty Acid Synthase (FASN)--catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents?
    Lupu R; Menendez JA
    Curr Pharm Biotechnol; 2006 Dec; 7(6):483-93. PubMed ID: 17168665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of a series of bioavailable fatty acid synthase (FASN) KR domain inhibitors for cancer therapy.
    Lu T; Schubert C; Cummings MD; Bignan G; Connolly PJ; Smans K; Ludovici D; Parker MH; Meyer C; Rocaboy C; Alexander R; Grasberger B; De Breucker S; Esser N; Fraiponts E; Gilissen R; Janssens B; Peeters D; Van Nuffel L; Vermeulen P; Bischoff J; Meerpoel L
    Bioorg Med Chem Lett; 2018 Jul; 28(12):2159-2164. PubMed ID: 29779975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virtual screening-based identification of novel fatty acid synthase inhibitor and evaluation of its antiproliferative activity in breast cancer cells.
    Amrutha Nisthul A; Archana PR; Anto RJ; Sadasivan C
    J Mol Graph Model; 2021 Jun; 105():107903. PubMed ID: 33780787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory effect of emodin on fatty acid synthase, colon cancer proliferation and apoptosis.
    Lee KH; Lee MS; Cha EY; Sul JY; Lee JS; Kim JS; Park JB; Kim JY
    Mol Med Rep; 2017 Apr; 15(4):2163-2173. PubMed ID: 28260110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanistic MALDI-TOF Cell-Based Assay for the Discovery of Potent and Specific Fatty Acid Synthase Inhibitors.
    Weigt D; Parrish CA; Krueger JA; Oleykowski CA; Rendina AR; Hopf C
    Cell Chem Biol; 2019 Sep; 26(9):1322-1331.e4. PubMed ID: 31279605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent Advances in the Development of Fatty Acid Synthase Inhibitors as Anticancer Agents.
    Singh S; Karthikeyan C; Moorthy NSHN
    Mini Rev Med Chem; 2020; 20(18):1820-1837. PubMed ID: 32781957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repositioning proton pump inhibitors as anticancer drugs by targeting the thioesterase domain of human fatty acid synthase.
    Fako VE; Wu X; Pflug B; Liu JY; Zhang JT
    J Med Chem; 2015 Jan; 58(2):778-84. PubMed ID: 25513712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An easy, rapid and objective mathematical method to identify fatty acid synthase (oncogenic antigen-519) modulators with potential anticancer value.
    Lupu R; Colomer R; Menéndez JA
    Clin Transl Oncol; 2008 Apr; 10(4):219-26. PubMed ID: 18411195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fenofibrate induces human hepatoma Hep3B cells apoptosis and necroptosis through inhibition of thioesterase domain of fatty acid synthase.
    You BJ; Hour MJ; Chen LY; Luo SC; Hsu PH; Lee HZ
    Sci Rep; 2019 Mar; 9(1):3306. PubMed ID: 30824767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cells.
    Veigel D; Wagner R; Stübiger G; Wuczkowski M; Filipits M; Horvat R; Benhamú B; López-Rodríguez ML; Leisser A; Valent P; Grusch M; Hegardt FG; García J; Serra D; Auersperg N; Colomer R; Grunt TW
    Int J Cancer; 2015 May; 136(9):2078-90. PubMed ID: 25302649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Inhibitor of Fatty Acid Synthase Thioesterase Domain with Improved Cytotoxicity against Breast Cancer Cells and Stability in Plasma.
    Lupien LE; Dunkley EM; Maloy MJ; Lehner IB; Foisey MG; Ouellette ME; Lewis LD; Pooler DB; Kinlaw WB; Baures PW
    J Pharmacol Exp Ther; 2019 Oct; 371(1):171-185. PubMed ID: 31300609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.